|Articles|August 1, 2003
Levofloxacin 1.5% concentration combats ocular pathogens
Fort Lauderdale, FL-Topical levofloxacin 1.5% (Santen), a new concentration of the drug in clinical development, achieves tear-fluid concentrations well above the reported minimum inhibitory concentrations (MIC) for the most common ocular pathogens, reported Tom R. Walters, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Closing the gap: John Berdahl, MD, on the global cataract burden and the emerging dementia connection
3
Treatment Goals in Retinal Vascular Diseases
4
Durability and Unmet Needs in Retinal Vascular Diseases
5

















